0001640455-18-000039.txt : 20180312
0001640455-18-000039.hdr.sgml : 20180312
20180312190607
ACCESSION NUMBER: 0001640455-18-000039
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180308
FILED AS OF DATE: 20180312
DATE AS OF CHANGE: 20180312
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Drapkin Kimberlee C
CENTRAL INDEX KEY: 0001340881
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37998
FILM NUMBER: 18684851
MAIL ADDRESS:
STREET 1: PREDIX PHARMACEUTICALS HOLDINGS, INC.
STREET 2: 4 MAGUIRE ROAD
CITY: LEXINGTON
STATE: MA
ZIP: 02421
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Jounce Therapeutics, Inc.
CENTRAL INDEX KEY: 0001640455
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 454870634
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 780 MEMORIAL DRIVE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 857-259-3840
MAIL ADDRESS:
STREET 1: 780 MEMORIAL DRIVE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
4
1
wf-form4_152089594368204.xml
FORM 4
X0306
4
2018-03-08
0
0001640455
Jounce Therapeutics, Inc.
JNCE
0001340881
Drapkin Kimberlee C
C/O JOUNCE THERAPEUTICS, INC.
780 MEMORIAL DRIVE
CAMBRIDGE
MA
02139
0
1
0
0
CFO and Treasurer
Common Stock
2018-03-08
4
M
0
3759
0.48
A
5267
D
Common Stock
2018-03-08
4
S
0
5267
25.01
D
0
D
Stock Option (Right to Buy)
0.48
2018-03-08
4
M
0
3759
0
D
2024-01-27
Common Stock
3759.0
3016
D
The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on June 8, 2017. The Reporting Person exercised no discretion with respect to these transactions.
Represents the weighted average share price of an aggregate total of 5,267 shares sold in the price range of $25.00 to $25.24 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission Staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
The option shares vested and became exercisable in 12 monthly installments from October 9, 2013.
/s/ Anna L. Barry, Attorney-in-Fact
2018-03-12